Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq: LFVN) reported Q1 fiscal 2026 results for the quarter ended Sept 30, 2025, with revenue $47.6M (+0.7% YoY; +0.3% ex-FX). Gross profit was $37.8M (79.5% of revenue). Net income was $2.2M or $0.17 diluted; adjusted EPS was $0.18. Adjusted EBITDA was $3.9M. Cash and equivalents were $13.1M at Sept 30, 2025; no debt outstanding. The company closed the strategic acquisition of LoveBiome and repurchased 44,000 shares for ~$0.6M. A cash dividend of $0.045 per share was declared, payable Dec 15, 2025. Fiscal 2026 guidance reiterated: revenue $225–240M, adjusted EBITDA $23–26M, adjusted EPS $1.00–1.15.

LifeVantage (Nasdaq: LFVN) concluded Momentum Academy 2025 in Dallas on Oct 23–25, 2025, bringing together thousands of Consultants to deliver new products, tools, and business strategies under the theme “Love Life & Drive.”

The event marked the first large in-person integration of LoveBiome Consultants after the companies began combining on Oct 1, 2025. Attendees trained on product pairing Protandim Nrf2 Synergizer with LoveBiome P84, and saw launches including LoveBiome P84 purchasable via LifeVantage, TrueScience Charcoal Refining Mask, and an updated AXIO Green Apple flavor.

LifeVantage (NASDAQ:LFVN) will release financial results for its fiscal first quarter ended September 30, 2025 after market close on Tuesday, November 4, 2025.

The company will hold an investor conference call on November 4, 2025 at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time). U.S. dial-in: (877) 704-4453; international dial-in: (201) 389-0920. A telephone replay will be available about two hours after the call through Tuesday, November 18, 2025 via U.S. replay (844) 512-2921 or international replay (412) 317-6671 using confirmation code 13756552.

A simultaneous live webcast will be available on the Investor Relations site at https://lifevantage.gcs-web.com/events-and-presentations or directly at the provided webcast link; the webcast archive will remain available for approximately 30 days.

LifeVantage (Nasdaq: LFVN) announced that Steve Fife, President and Chief Executive Officer, will participate in the LD Micro Main Event XIX in San Diego, October 19-21, 2025.

Mr. Fife will meet with investors and present at approximately 5:30 p.m. Eastern Time on Monday, October 20, 2025. A live webcast will be available on the company’s Investor Relations News & Events page at https://lifevantage.gcs-web.com, and a replay will be archived on the company website.

LifeVantage (Nasdaq:LFVN) has completed its acquisition of LoveBiome, a direct sales company specializing in microbiome care and wellness solutions. The strategic acquisition includes LoveBiome's core operating assets and key personnel retention.

The merger combines LoveBiome's innovative P84 product and microbiome solutions with LifeVantage's Activation technologies, strengthening the company's position in the growing gut health market. The deal expands LifeVantage's market presence in the US, Taiwan, and Europe, with LoveBiome's founder Kelly Olsen joining forces to drive growth initiatives.

LifeVantage (Nasdaq: LFVN), a health and wellness company focused on cellular health, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference. The virtual event will feature President and CEO Steve Fife and CFO Carl Aure, who will conduct investor meetings and deliver a presentation on September 30, 2025, at 11:00 a.m. ET.

Investors can access the live webcast through the company's Investor Relations website, with a replay available after the event.

LifeVantage (Nasdaq: LFVN) reported strong financial results for Q4 and fiscal year 2025. Q4 revenue increased 12.6% to $55.1 million, with the Americas growing 14.1% and Asia/Pacific & Europe up 7.6%. Full fiscal year 2025 revenue rose 14.2% to $228.5 million, with net income per diluted share of $0.75 compared to $0.23 in 2024.

The company maintained a strong balance sheet with $20.2 million in cash and no debt. Key highlights include adjusted EBITDA of $22.1 million (up 30.3%) and successful international expansion with the MindBody System rollout. The company declared a dividend of $0.045 per share and provided FY2026 guidance projecting revenue between $225-240 million and adjusted earnings per share of $1.00-1.15.

LifeVantage (Nasdaq:LFVN) has announced a strategic acquisition of LoveBiome, a direct sales company specializing in microbiome health solutions. The acquisition strengthens LifeVantage's position in the rapidly growing gut health market, which is projected to expand from $14.4 billion in 2025 to $32.4 billion by 2035.

The deal centers around LoveBiome's P84 product, which focuses on gut health regulation and restoration through Activation technology, complementing LifeVantage's existing portfolio including Protandim® and MindBody GLP-1 System™. The transaction is expected to close by mid-October 2025 and will be accretive to Adjusted EPS and EBITDA in the first year.

LifeVantage (Nasdaq: LFVN), a health and wellness company focused on cellular health products, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, in New York, NY.

President and CEO Steve Fife, along with CFO Carl Aure, will conduct investor meetings and deliver a presentation on Wednesday, September 10, 2025, at 1:00 p.m. Eastern Time. The presentation will be available via live webcast on the company's investor relations website, with a replay accessible for approximately 90 days afterward.